Home News

ROVI completes the manufacture of the first batches of Moderna vaccine

Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological

Wed, 13/01/2021 - 17:03 0 min
Download related document
No votes yet
 
Related
ROVI held its 2025 General Shareholders’ Meeting
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
First three months 2025 results press release
​Operating revenue in the first quarter of 2025 was 154.9 million euros, a 2% increase on the first quarter of 2024, mainly due to the...
2 min
08/05/2025
2025 Capital Markets Day presentation
ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase...
1 min
25/03/2025